Nnamdi Eze1, Ju-Whei Lee2, Dong-Hua Yang3, Fang Zhu4, Veronique Neumeister5, Teresa Sandoval-Schaefer1, Ranee Mehra6, John A Ridge7, Arlene Forastiere8, Christine H Chung9, Barbara Burtness10. 1. Department of Medicine, Yale University School of Medicine and Yale Cancer Center, United States. 2. Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, ECOG-ACRIN Biostatistics Center, United States. 3. Biosample Repository, Fox Chase Cancer Center, United States. 4. Department of Biostatistics, Fox Chase Cancer Center, United States. 5. Department of Pathology, Yale University School of Medicine, United States. 6. Department of Medical Oncology, Fox Chase Cancer Center, United States. 7. Department of Surgical Oncology, Fox Chase Cancer Center, United States. 8. Departments of Medicine, Radiation Oncology and Otolaryngology, Sidney Kimmel Cancer Center, Johns Hopkins University, United States. 9. Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, United States. 10. Department of Medicine, Yale University School of Medicine and Yale Cancer Center, United States. Electronic address: barbara.burtness@yale.edu.
Abstract
INTRODUCTION:Cetuximab, a monoclonal antibody to the epidermal growth factor receptor (EGFR), extends survival in combination with standard therapy in head and neck squamous cell carcinoma (HNSCC). However, as effects are modest, and patients experience side effects, a biomarker to predict resistance and personalize therapy is needed. Activation of signaling pathways downstream from receptor tyrosine kinases predicts resistance to such therapies in other cancers. The most common abnormalities downstream from EGFR in HNSCC are in the PI3K pathway, activated via loss of expression of the regulator PTEN, or via PI3K mutation. We studied whether PTEN and/or PI3K abnormalities predict resistance to cetuximab. METHODS: Tumor PTEN and PIK3CA/PI3K p110α were analyzed in samples from subjects treated on two trials of cetuximab-based therapy for patients with metastatic or recurrent HNSCC: E5397, a randomized trial of cisplatin plus placebo versus cisplatin plus cetuximab; and NCI-8070, a randomized trial of cetuximab plus sorafenib versus cetuximab. In situ quantification of PTEN and PI3K p110 α was performed using the AQUA™ method of quantitative immunofluorescence. PI3KCA hot spot mutations were determined with BEAMing. RESULTS: For E5397, in multivariable analysis, PTEN expressing/PIK3CA WT patients tended to improve PFS with cetuximab compared to placebo (N = 48; HR = 0.54, Wald p = 0.0502). High PTEN expression was significantly associated with superior PFS among patients treated on NCI-8070 (N = 37; HR = 0.35, p = 0.008). CONCLUSION: Loss of PTEN expression may be associated with lack of benefit from cetuximab. This analysis is limited by small sample size, and PTEN as a potential predictive biomarker merits validation in larger sample sets.
RCT Entities:
INTRODUCTION:Cetuximab, a monoclonal antibody to the epidermal growth factor receptor (EGFR), extends survival in combination with standard therapy in head and neck squamous cell carcinoma (HNSCC). However, as effects are modest, and patients experience side effects, a biomarker to predict resistance and personalize therapy is needed. Activation of signaling pathways downstream from receptor tyrosine kinases predicts resistance to such therapies in other cancers. The most common abnormalities downstream from EGFR in HNSCC are in the PI3K pathway, activated via loss of expression of the regulator PTEN, or via PI3K mutation. We studied whether PTEN and/or PI3K abnormalities predict resistance to cetuximab. METHODS:TumorPTEN and PIK3CA/PI3K p110α were analyzed in samples from subjects treated on two trials of cetuximab-based therapy for patients with metastatic or recurrent HNSCC: E5397, a randomized trial of cisplatin plus placebo versus cisplatin plus cetuximab; and NCI-8070, a randomized trial of cetuximab plus sorafenib versus cetuximab. In situ quantification of PTEN and PI3K p110 α was performed using the AQUA™ method of quantitative immunofluorescence. PI3KCA hot spot mutations were determined with BEAMing. RESULTS: For E5397, in multivariable analysis, PTEN expressing/PIK3CA WT patients tended to improve PFS with cetuximab compared to placebo (N = 48; HR = 0.54, Wald p = 0.0502). High PTEN expression was significantly associated with superior PFS among patients treated on NCI-8070 (N = 37; HR = 0.35, p = 0.008). CONCLUSION: Loss of PTEN expression may be associated with lack of benefit from cetuximab. This analysis is limited by small sample size, and PTEN as a potential predictive biomarker merits validation in larger sample sets.
Authors: Floyd Christopher Holsinger; Sarina Anne Piha-Paul; Filip Janku; David S Hong; Johnique T Atkins; Apostolia M Tsimberidou; Razelle Kurzrock Journal: J Clin Oncol Date: 2013-01-28 Impact factor: 44.544
Authors: Nicolas Stransky; Ann Marie Egloff; Aaron D Tward; Aleksandar D Kostic; Kristian Cibulskis; Andrey Sivachenko; Gregory V Kryukov; Michael S Lawrence; Carrie Sougnez; Aaron McKenna; Erica Shefler; Alex H Ramos; Petar Stojanov; Scott L Carter; Douglas Voet; Maria L Cortés; Daniel Auclair; Michael F Berger; Gordon Saksena; Candace Guiducci; Robert C Onofrio; Melissa Parkin; Marjorie Romkes; Joel L Weissfeld; Raja R Seethala; Lin Wang; Claudia Rangel-Escareño; Juan Carlos Fernandez-Lopez; Alfredo Hidalgo-Miranda; Jorge Melendez-Zajgla; Wendy Winckler; Kristin Ardlie; Stacey B Gabriel; Matthew Meyerson; Eric S Lander; Gad Getz; Todd R Golub; Levi A Garraway; Jennifer R Grandis Journal: Science Date: 2011-07-28 Impact factor: 47.728
Authors: Eric Van Cutsem; Heinz-Josef Lenz; Claus-Henning Köhne; Volker Heinemann; Sabine Tejpar; Ivan Melezínek; Frank Beier; Christopher Stroh; Philippe Rougier; J Han van Krieken; Fortunato Ciardiello Journal: J Clin Oncol Date: 2015-01-20 Impact factor: 44.544
Authors: Renato G Martins; Upendra Parvathaneni; Julie E Bauman; Anand K Sharma; Luis E Raez; Michael A Papagikos; Furhan Yunus; Brenda F Kurland; Keith D Eaton; Jay J Liao; Eduardo Mendez; Neal Futran; David X Wang; Xiaoyu Chai; Sarah G Wallace; Melissa Austin; Rodney Schmidt; D Neil Hayes Journal: J Clin Oncol Date: 2013-03-04 Impact factor: 44.544
Authors: Simion I Chiosea; Jennifer R Grandis; Vivian W Y Lui; Brenda Diergaarde; Jessica H Maxwell; Robert L Ferris; Seungwon W Kim; Alyssa Luvison; Megan Miller; Marina N Nikiforova Journal: BMC Cancer Date: 2013-12-17 Impact factor: 4.430
Authors: Paul L Swiecicki; Pin Li; Emily Bellile; Chaz Stucken; Kelly Malloy; Andrew Shuman; Matthew E Spector; Steven Chinn; Keith Casper; Scott McLean; Jeffery Moyer; Douglas Chepeha; Gregory T Wolf; Mark Prince; Carol Bradford; Mukesh Nyati; Avraham Eisbruch; Francis P Worden; Shruti Jolly; Michelle Mierzwa Journal: Head Neck Date: 2020-01-27 Impact factor: 3.147
Authors: Khoa A Nguyen; Madison J Keith; Stephen B Keysar; Spencer C Hall; Anamol Bimali; Antonio Jimeno; Xiao-Jing Wang; Christian D Young Journal: Mol Carcinog Date: 2022-04-13 Impact factor: 5.139
Authors: Mihály Cserepes; Györgyi A Nelhűbel; Mónika Meilinger-Dobra; Adrienn Herczeg; Dóra Türk; Zita Hegedűs; Laura Svajda; Erzsébet Rásó; Andrea Ladányi; Kristóf György Csikó; István Kenessey; Árpád Szöőr; György Vereb; Éva Remenár; József Tóvári Journal: Cancers (Basel) Date: 2022-05-13 Impact factor: 6.575
Authors: Hasan Baysal; Ines De Pauw; Hannah Zaryouh; Marc Peeters; Jan Baptist Vermorken; Filip Lardon; Jorrit De Waele; An Wouters Journal: Front Immunol Date: 2021-09-07 Impact factor: 7.561